目的:目的研究167例乙肝病毒截短型表面抗原中蛋白(C-terminally truncated middle size surface proteins,MHBst167)和X蛋白(hepatitis B virus X protein,HBx)对肾小管上皮细胞核转录因子κB(nuclear factor-kappaB,NF-κB)活化的影...目的:目的研究167例乙肝病毒截短型表面抗原中蛋白(C-terminally truncated middle size surface proteins,MHBst167)和X蛋白(hepatitis B virus X protein,HBx)对肾小管上皮细胞核转录因子κB(nuclear factor-kappaB,NF-κB)活化的影响及其相关机制探讨。方法:肾小管上皮细胞系(HK-2)转染mhbst167或(和)hbx后,蛋白印迹法检测NF-κB核易位及其抑制蛋白(inhibitor of nuclear factor-kappa B,IκBα)磷酸化水平的变化,凝胶电泳迁移率和双萤光素酶报告基因分析进一步检测NF-κB活性;通过对蛋白激酶C(protein kinase C,PKC)活性和细胞外调节激酶(extracellular regulated protein kinases,ERK)磷酸化水平检测探讨NF-κB活化的机制。结果:HK-2细胞转染mhbst167或(和)hbx基因后,NF-κB核易位、磷酸化IκBα、κB结合活性及κB基因转录均增加(P<0.05);且PKC激酶活性和磷酸化ERK水平也增加(P<0.05),而Raf蛋白均无表达。结论:在肾小管上皮细胞中,MHBst167/HBx可能通过PKC/ERK通路(非Raf依赖性)活化NF-κB。展开更多
BACKGROUND： The long-term use of nudeos（t）ide analogues causes drug resistance and mutations in the HBV reverse tran- scriptase （RT） region of the polymerase gene. The RT region overlaps the HBV surface gene （S ...BACKGROUND： The long-term use of nudeos（t）ide analogues causes drug resistance and mutations in the HBV reverse tran- scriptase （RT） region of the polymerase gene. The RT region overlaps the HBV surface gene （S gene） and therefore, the mutations in the RT region simultaneously modify S gene sequence. Certain mutations in the RT region bring about truncated S proteins because the corresponding changed S gene encodes a stop codon which results in the loss of a large portion of the C-terminal hydrophobic region of HBV surface protein. The rtA181T/sW172＊, rtM204I/sW196＊ and rtV191I/sW182＊ are the most frequently reported drug-resistant mutations with C-terminal truncation, these mutations have oncogenic potential. DATA SOURCES： PubMed and Web of Science were searched using terms： ＂hepatitis B virus＂, ＂HBV drug resistance mutation＂ ＂HBV surface protein＂ ＂HBV truncation＂, ＂hepatocellular carcinoma＂, ＂rtA181T/sW172＊＂, ＂rtM204I/sW196＊＂, ＂rtV191I/sW182＊＂, and relevant articles published in English in the past decades were reviewed. RESULTS： The rtA181T/sW172＊ and rtV191I/sW182＊ mutants occurred more frequently than the rtM204I/sW196＊ mutant both in chronic hepatitis B patients and the HBV-related hepatocellular carcinoma tissues. Although these mutations occur naturally, nudeos（t）ide analogues therapy is the main driving force. These mutations may exist alone or coexist with other HBV mutations. All these three mutants impair the virion secretion and result in HBV surface protein retention and serum HBV DNA level reduction. These mutations possess potential carcinogenic properties. The three mutations are resistant to more than one nucleos（t）ide analogue and therefore, it is difficult to treat the patients with the truncated mutations.CONCLUSIONS： Nucleos（t）ide analogues induce drug resistance and HBV S gene truncated mutations. These mutations have potential carcinogenesis.展开更多
文摘目的:目的研究167例乙肝病毒截短型表面抗原中蛋白(C-terminally truncated middle size surface proteins,MHBst167)和X蛋白(hepatitis B virus X protein,HBx)对肾小管上皮细胞核转录因子κB(nuclear factor-kappaB,NF-κB)活化的影响及其相关机制探讨。方法:肾小管上皮细胞系(HK-2)转染mhbst167或(和)hbx后,蛋白印迹法检测NF-κB核易位及其抑制蛋白(inhibitor of nuclear factor-kappa B,IκBα)磷酸化水平的变化,凝胶电泳迁移率和双萤光素酶报告基因分析进一步检测NF-κB活性;通过对蛋白激酶C(protein kinase C,PKC)活性和细胞外调节激酶(extracellular regulated protein kinases,ERK)磷酸化水平检测探讨NF-κB活化的机制。结果:HK-2细胞转染mhbst167或(和)hbx基因后,NF-κB核易位、磷酸化IκBα、κB结合活性及κB基因转录均增加(P<0.05);且PKC激酶活性和磷酸化ERK水平也增加(P<0.05),而Raf蛋白均无表达。结论:在肾小管上皮细胞中,MHBst167/HBx可能通过PKC/ERK通路(非Raf依赖性)活化NF-κB。
基金supported by a grant from the National Natural Science Foundation of China(81071363)
文摘BACKGROUND： The long-term use of nudeos（t）ide analogues causes drug resistance and mutations in the HBV reverse tran- scriptase （RT） region of the polymerase gene. The RT region overlaps the HBV surface gene （S gene） and therefore, the mutations in the RT region simultaneously modify S gene sequence. Certain mutations in the RT region bring about truncated S proteins because the corresponding changed S gene encodes a stop codon which results in the loss of a large portion of the C-terminal hydrophobic region of HBV surface protein. The rtA181T/sW172＊, rtM204I/sW196＊ and rtV191I/sW182＊ are the most frequently reported drug-resistant mutations with C-terminal truncation, these mutations have oncogenic potential. DATA SOURCES： PubMed and Web of Science were searched using terms： ＂hepatitis B virus＂, ＂HBV drug resistance mutation＂ ＂HBV surface protein＂ ＂HBV truncation＂, ＂hepatocellular carcinoma＂, ＂rtA181T/sW172＊＂, ＂rtM204I/sW196＊＂, ＂rtV191I/sW182＊＂, and relevant articles published in English in the past decades were reviewed. RESULTS： The rtA181T/sW172＊ and rtV191I/sW182＊ mutants occurred more frequently than the rtM204I/sW196＊ mutant both in chronic hepatitis B patients and the HBV-related hepatocellular carcinoma tissues. Although these mutations occur naturally, nudeos（t）ide analogues therapy is the main driving force. These mutations may exist alone or coexist with other HBV mutations. All these three mutants impair the virion secretion and result in HBV surface protein retention and serum HBV DNA level reduction. These mutations possess potential carcinogenic properties. The three mutations are resistant to more than one nucleos（t）ide analogue and therefore, it is difficult to treat the patients with the truncated mutations.CONCLUSIONS： Nucleos（t）ide analogues induce drug resistance and HBV S gene truncated mutations. These mutations have potential carcinogenesis.
